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IMPORTANCE More than 1 billion people worldwide have vision impairment or blindness
from potentially preventable or correctable causes. Quality of life, an important measure of
physical, emotional, and social well-being, appears to be negatively associated with vision
impairment, and increasingly, ophthalmic interventions are being assessed for their
association with quality of life.
OBJECTIVE To examine the association between vision impairment or eye disease and quality
of life, and the outcome of ophthalmic interventions on quality of life globally and across the
life span, through an umbrella review or systematic review of systematic reviews.
EVIDENCE REVIEW The electronic databases MEDLINE, Ovid, Embase, Cochrane Database of
Systematic Reviews, Proquest Dissertations, and Theses Global were searched from inception
through June 29, 2020, using a comprehensive search strategy. Systematic reviews
addressing vision impairment, eye disease, or ophthalmic interventions and quantitatively
or qualitatively assessing health-related, vision-related, or disease-specific quality of life
were included. Article screening, quality appraisal, and data extraction were performed by
4 reviewers working independently and in duplicate. The Joanna Briggs Institute critical
appraisal and data extraction forms for umbrella reviews were used.
FINDINGS Nine systematic reviews evaluated the association between quality of life and vision
impairment, age-related macular degeneration, glaucoma, diabetic retinopathy, or mendelian
eye conditions (including retinitis pigmentosa). Of these, 5 were reviews of quantitative
observational studies, 3 were reviews of qualitative studies, and 1 was a review of qualitative
and quantitative studies. All found an association between vision impairment and lower
quality of life. Sixty systematic reviews addressed at least 1 ophthalmic intervention in
association with quality of life. Overall, 33 unique interventions were investigated, of which
25 were found to improve quality of life compared with baseline measurements or a group
receiving no intervention. These interventions included timely cataract surgery, anti–vascular
endothelial growth factor therapy for age-related macular degeneration, and macular edema.
CONCLUSIONS AND RELEVANCE There is a consistent association between vision impairment,
eye diseases, and reduced quality of life. These findings support pursuing ophthalmic
interventions, such as timely cataract surgery and anti–vascular endothelial growth factor
therapy, for common retinal diseases, where indicated, to improve quality of life for millions
of people globally each year.
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A t least 2.2 billion people worldwide have a vision im-pairment, of whom more than 1 billion have moderateor severe vision impairment or blindness from a pre-
ventable or potentially correctable cause, including refractive
error, presbyopia, and cataract.1 Existing evidence suggests that
vision impairment is associated with lower quality of life,2 de-
fined as physical, emotional, and social well-being. Visual im-
pairment is also linked to lower vision-related quality of life3 or
daily visual function and the ability to perform visual tasks.
Over the past decade, quality-of-life measures have gained
popularity in ophthalmology research, including clinical trials,
as the value of patient-reported outcomes in measuring well-
being and visual function is being recognized.4 However, to
our knowledge, there has yet to be a global synthesis of the evi-
dence about quality of life and eye health, despite the numer-
ous systematic reviews about vision impairment, eye dis-
eases, or ophthalmic interventions and quality of life.5-7
Therefore, the objective of this umbrella review, which is
a systematic review of systematic reviews, is to examine the
association between vision impairment or specific eye dis-
eases and reduced quality of life, and the effectiveness that
ophthalmic interventions can have on improving quality of life.
Methods
This study forms part of the work for the forthcoming Lancet
Global Health Commission on Global Eye Health.8 We fol-
lowed the Preferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) reporting guidelines (eAppendix 1
in the Supplement). A protocol was published9 and regis-
tered on the Open Science Framework Registries (https://osf.
io/qhv9g). Changes to the protocol are noted in eAppendix 2
in the Supplement.
A comprehensive search was performed using the elec-
tronic databases MEDLINE, Ovid, Embase, Cochrane Data-
base of Systematic Reviews, Proquest Dissertations, and
Theses Global from inception through June 29, 2020 (a sample
search strategy is in the eAppendix 3 in the Supplement). Open-
Grey, the Agency for Healthcare Research and Quality, and ref-
erences of included reviews were searched for additional
articles. Inclusion and exclusion criteria are listed in Table 1.
Study selection, quality appraisal, and data collection
were performed by 4 reviewers (L.A., F.C., P.I., and H.S.)
independently and in duplicate using Covidence software
(Covidence Inc).10 Titles and abstracts were screened to iden-
tify potentially relevant articles. Full texts of these articles were
assessed for eligibility based on the inclusion and exclusion
criteria. Reviews that aimed to identify studies with quality-
of-life outcomes but did not find any were excluded, since they
had no results to be extracted.
Reviews underwent quality appraisal using the Joanna
Briggs Institute Critical Appraisal Checklist for Systematic
Reviews and Research Syntheses.11 Reviews for which any of
the items “clear review question,” “appropriate inclusion cri-
teria,” “appropriate search strategy,” or “appropriate criteria
for critical appraisal” were graded as unclear or no were ex-
cluded. Data collection was performed using the Joanna Briggs
Institute Data Extraction Form for Systematic Reviews and
Research Syntheses.12
Results of the reviews on vision impairment or eye dis-
eases and ophthalmic interventions were presented sepa-
rately. Within the reviews on ophthalmic interventions, 2 types
of comparisons were identified: (1) those that compared the
quality of life of a group receiving an intervention with base-
line quality of life in the same group or a control group receiv-
ing no intervention, a placebo, or sham therapy and (2) those
Table 1. Inclusion and Exclusion Criteria
Characteristic Inclusion criteria Exclusion criteria
Study type Systematic reviews, defined
as reviews that include all of









Reviews that did not meet
the working definition of
a systematic review;
systematic reviews that
included case series or
expert opinion pieces
Population Systematic reviews with
participants with vision














aim to improve or preserve

















of physical, emotional, and
social well-being and vision





Other None Conference abstracts and
articles not in English;
systematic reviews that had
an updated version available
(they were used as an
additional reference only if
the updated review referred
to them)
Key Points
Question What is the association between vision impairment,
eye diseases, or ophthalmic interventions and quality of life?
Findings In this cross-sectional study of systematic reviews,
vision impairment and eye diseases were associated with lower
quality of life. More than half of the ophthalmic interventions
included had a positive association with quality of life.
Meaning The associations of quality of life with vision impairment
and the improvements in quality of life with ophthalmic
interventions support efforts to improve access to ophthalmic
treatments globally to reach the millions of people affected by
eye disease each year.
Research Original Investigation A Global Assessment of Eye Health and Quality of Life
E2 JAMA Ophthalmology Published online February 12, 2021 (Reprinted) jamaophthalmology.com
Downloaded From: https://jamanetwork.com/ on 02/15/2021
that compared the quality of life of a group receiving 1 inter-
vention with a group receiving another intervention, without
comparison with a baseline or a group that received no inter-
vention. Results from each type of comparison were de-
scribed separately, and only comparisons with baseline or a
group receiving no intervention were included in the Tables
summarizing findings (Table 2).
When the same intervention or outcome was assessed by
more than 1 review, the primary studies used by the reviews
to inform the results were compared to assess the extent to
which individual studies were included in more than 1 re-
view. Results about associations were based on the reviews’
interpretation of the estimates and accompanied by the mea-
sure of association and quality of the evidence assessment
when available in the published review. Overall findings were
presented in the Box and Table 3.
Results
As described in the PRISMA flowchart (eFigure in the Supple-
ment), 8070 unique titles and abstracts were screened; of
these, 685 relevant full-text articles were assessed for eligibil-
ity. Ten eligible systematic reviews addressed quality of life
and vision impairment or eye diseases, and 205 assessed
ophthalmic interventions. Of the reviews concerning oph-
thalmic interventions, 143 were excluded because they did
not identify any eligible studies with quality-of-life data in
the literature.
Results of the quality assessment are presented in eTable 1
in the Supplement. Three reviews were excluded, 2 for not hav-
ing appropriate critical appraisal criteria, and 1 for not having
appropriate inclusion criteria. This left 9 reviews on vision
impairment or eye diseases and 60 reviews on ophthalmic
interventions included in the current analysis. Review char-
acteristics are summarized in eTable 2 in the Supplement.
Vision Impairment and Eye Diseases
In total, 9 systematic reviews6,7,47-53 published between 2010
and 2020 evaluated the association between vision impair-
ment or eye disease and quality of life. Four of them had cor-
responding authors in the UK7,47,51,52; the rest were in the US,53
Netherlands,48 Taiwan,49 China,50 and Singapore.6 Five6,47-50
were systematic reviews of observational quantitative stud-
ies, 37,51,52 were reviews of qualitative studies, and 153 was a
review of both quantitative and qualitative studies (Table 4).
None of the reviews graded the quality of the evidence.
The systematic reviews of observational quantitative stud-
ies focused on people with vision impairment, including
adults48 and specifically working-age47 and older adults,49
people with glaucoma,50 diabetic retinopathy,6 and children
and adults with mendelian eye conditions, including retinitis
pigmentosa, Usher syndrome, and mixed retinal dystrophies.53
Among all the populations examined, vision impairment or eye
diseases were associated with lower quality of life, including
vision-related and health-related49 and glaucoma-specific50
quality of life. Moreover, people with vision impairment had
poorer scores on quality-of-life subscales, such as mental
health,47 psychosocial functioning,6 and fatigue (odds ratio,
2.61 [95% CI, 1.69-4.04]).48
The systematic reviews of qualitative studies assessed
emotional well-being and daily functioning among older adults
with vision impairment7 and age-related macular degenera-
tion (AMD)51 and children and adults with mendelian eye
conditions,53 including retinitis pigmentosa specifically in
a second review.52 The 2 reviews52,53 that addressed retinitis
pigmentosa included 2 overlapping primary studies. Emo-
tional well-being among people with vision impairment, AMD,
and retinitis pigmentosa was especially affected at the initial
diagnosis, which was described as a shocking or traumatic
event in the 3 reviews.7,51,52 Moreover, coping with AMD and
retinitis pigmentosa was associated with negative thoughts,
including depressive symptoms, fatigue, and isolation.51,52
Vision impairment and mendelian eye conditions specifi-
cally also affected general daily functioning; people reported
having to relinquish their independence and giving up on
leisure activities.7,52,53 Difficulties performing visual tasks, such
as reading and seeing in changing light conditions, were also
reported by people with retinitis pigmentosa.52
Overall, 5 exposures (vision impairment; AMD; diabetic
retinopathy; mendelian eye conditions, including retinitis
pigmentosa; and glaucoma) were evaluated for their associa-
tion with quality of life. A summary of findings is presented
in the Box.
Ophthalmic Interventions
In total, 60 systematic reviews published between 2005 and
2020 evaluated ophthalmic interventions using quality-of-
life outcomes. Seventeen had corresponding authors in the
UK,18,19,23,26,28,29,32,37,42-44,46,54-59 13 in the US,13,20,21,38-40,60-66
6 in China,24,27,30,67-69 6 in Italy,22,25,70-73 3 in Brazil,34,45,74
3 in Canada,14,15,17 2 in Denmark,75,76 2 in Spain,33,42 and 1 each
in Uruguay,41 Switzerland,16 Bahrain,73 Germany,77 Belgium,31
the Netherlands,36 Taiwan,35 and Australia.78 Thirty-nine
reviews reported vision-related quality-of-life measures13,15,
16,19,21-34,37,42,44,54,55,58-62,66-71,73-77; 7, disease-specific
measures35,38-41,57,65; 4, generic measures14,45,56,72; and 10, more
than 1 measure type.17,18,20,36,43,46,63,64,78,79 Reviews that
assessed and reported the quality of the evidence either used
the Grading of Recommendations, Assessment, Develop-
ment, and Evaluations (GRADE) tool with 4 possible levels of
evidence (very low, low, moderate, or high)80 or the US Pre-
ventive Services Task Force scale for overall quality of the evi-
dence (poor, fair, or good).81
Findings about quality of life after ophthalmic interven-
tions compared with quality of life at baseline or in a group re-
ceiving no intervention are presented in Table 2 and eTable 4
in the Supplement. Seven systematic reviews13-19 addressed
interventions for age-associated cataract. One review13 found
improvement in vision-related quality of life after treatment
of early vision impairment attributable to cataract in 3 of the
5 studies included (with fair-quality evidence). Two reviews14,15
using results from the same primary studies showed im-
proved vision-related quality of life in the group receiving
expedited cataract surgery compared with the control group
with a routine waiting time for surgery, and a third16 found
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benefits to immediate cataract surgery among people with AMD
specifically, compared with those having no or delayed sur-
gery (low-quality evidence). Two reviews17,18 with some over-
lap of primary studies found a nonclinically meaningful im-
provement in vision-related quality of life after a second eye
cataract surgery compared with surgery in 1 eye only (with
moderate-quality evidence in 1 review17). Both extracapsular
cataract extraction with posterior chamber intraocular lens
(IOL) implantation and intracapsular cataract extraction with
aphakic glasses were associated with improvement in vision-
related quality-of-life outcomes, but extracapsular cataract
extraction resulted in greater improvement.19 Only 1 system-
atic review assessed interventions associated with refractive
error. Using corrective lenses for vision impairment because
of uncorrected refractive error improved vision-related qual-
ity of life (fair-quality evidence).13
Seven systematic reviews13,20-24,54 assessed interven-
tions for AMD. Anti–vascular endothelial growth factor (anti-
VEGF) therapy was associated with improved vision-related
quality of life compared with no anti-VEGF therapy in 2
reviews,13-20 with some overlap in primary studies (de-
scribed as mild to moderate improvements, with fair-quality
evidence13 and moderate-quality evidence20). Treatment using
aflibercept and ranibizumab resulted in improved vision-
related quality of life from baseline to a similar extent (high-
quality evidence that quality of life is similar in both groups).21
Macular surgery compared with observation (relative risk, 1.35
[95% CI, 1.09-1.68]; low-quality evidence),22 and antioxidant
vitamin supplementation compared with placebo (low-
quality evidence)23 were associated with improved vision-
related quality of life, while radiotherapy compared with
Box. Summary of Findings From Systematic Reviews of Vision
Impairment or Eye Disease Associated With Lower Quality of Life
Vision Impairment
• Vitality subscale (fatigue) of health-related quality of life among
adults with vision impairment48
• Mental health subscale of health-related and vision-related
quality of life among working-age adults with vision
impairment47
• Vision-related and health-related quality of life among older
adults with vision impairment49
• Emotional well-being and general functioning among older
adults with vision impairment7
Age-Related Macular Degeneration
• Emotional well-being among people with age-related macular
degeneration51
Diabetic Retinopathy
• Psychosocial functioning among people with diabetic
retinopathy6
Mendelian Eye Conditions
• Emotional well-being among people with retinitis pigmentosa52
• General and visual functioning among people with mendelian
eye conditions, including retinitis pigmentosa53
Glaucoma
• Glaucoma-specific quality of life among people with glaucoma50
Table 3. Summary of Findings From Systematic Reviews
of Ophthalmic Interventions
Area




Cataract surgery for the treatment
of early impairment in visual
acuity (1); expedited cataract
surgery vs awaiting cataract
surgery (routine wait time) (2);
expedited surgery vs routine wait
time among people with
age-related macular degeneration
(1); second-eye surgery vs surgery
in 1 eye only (2); cataract surgery
by extracapsular cataract
extraction with posterior chamber
intraocular lens or intracapsular











Anti-VEGF vs no anti-VEGF (2);
aflibercept or ranibizumab (1);








Retina (other) Anti-VEGF or laser
photocoagulation for diabetic
retinopathy (1); anti-VEGF vs
sham for macular edema
secondary to central retinal vein
occlusion (3); anti-VEGF vs sham
for macular edema secondary to
branch retinal vein occlusion (1);
anti-VEGF vs sham for choroidal
neovascularization secondary
to pathological myopia (1);
ocriplasmin injection vs sham
for symptomatic vitreomacular
traction (1); ocriplasmin injection







Glaucoma None Laser trabeculoplasty
and topic β-blockers








Low vision Multidisciplinary rehabilitation
vs waiting list or no care (1);
methods of enhancing vision
(eg, low-vision service,
customized prism glasses) vs
waiting list or no care (1)
None
Vision screening Ready-made spectacles or
custom-made spectacles after
school vision screening (1)
None
Rhinoconjunctivitis Subcutaneous immunotherapy
vs placebo (2); Sublingual
immunotherapy vs placebo (all
ages) (1); intranasal fluticasone
furoate vs placebo for seasonal
allergic rhinitis (1); intranasal
fluticasone furoate vs placebo

















Abbreviations: anti-VEGF, anti–vascular endothelial growth factor;
QOL, quality of life.
a Number of systematic reviews informing the intervention and outcome are
shown in parentheses.
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observation54 was not. Two reviews23,24 with some overlap of
primary studies found that supplementation with lutein and/or
zeaxanthin compared with placebo was not associated with
better vision-related quality of life (with low-quality evi-
dence in 1 review23).
Nine systematic reviews25-33 examined interventions for
other retinal diseases. One systematic review reported that both
anti-VEGF therapy and laser photocoagulation improved vision-
related quality of life for diabetic retinopathy, but anti-VEGF
therapy resulted in a greater improvement (moderate-quality
evidence).25 Likewise,3reviews26-28 usingidenticalprimarystud-
ies found that anti-VEGF therapy, compared with a sham treat-
ment, was associated with improvement in vision-related qual-
ity of life in people with macular edema secondary to central
retinal vein occlusion (high-quality evidence in 1 review27 and
moderate-quality evidence in another review26). Anti-VEGF
therapy was also found to improve vision-related quality of
life in those with branch retinal vein occlusion29 and choroidal
neovascularizationsecondarytopathologicalmyopia(moderate-
qualityevidence).30 Ocriplasmininjectioncomparedwithasham
treatment was associated with clinically meaningful improve-
ment in vision-related quality of life among those with sympto-
matic vitreomacular traction31 and adhesion (moderate-quality
evidence).32 Inpeoplewithhereditaryretinaldystrophies,vision-
related quality of life was similar among those who received
nutritional supplementation and placebo.33
Two systematic reviews34,35 addressed glaucoma inter-
ventions. Treatment of early open-angle glaucoma with laser
trabeculoplasty and topical β-blockers compared with pla-
cebo was not associated with differences in vision-related qual-
ity of life.34 Selective laser trabeculoplasty and/or medica-
tion use did not result in changes in disease-specific quality
of life in open-angle glaucoma.35
One systematic review36 addressed vision rehabilitation
interventions. Compared with a passive control arm (delayed
or no care), methods for enhancing vision (eg, low-vision ser-
vice, customized prism glasses) resulted in an imprecisely es-
timated benefit in vision-related quality of life (very low-
quality evidence), and multidisciplinary rehabilitation resulted
in beneficial vision-related quality-of-life effects (with very
low-quality evidence).36
One systematic review37 addressed vision screening. After-
school vision screenings and the use of ready-made or custom-
made spectacles both resulted in improvement in vision-
related quality of life to a similar extent (with moderate-
quality evidence that quality of life was similar in both
groups).37
Subcutaneous immunotherapy for rhinoconjunctivitis was
shown to result in greater improvement in rhinoconjunctivitis-
specific quality of life compared with placebo among chil-
dren in 1 systematic review39 (low-quality evidence) and among
adults in another review38 (high-quality evidence). Sublin-
gual immunotherapy was associated with better quality of life
in 1 review40 (moderate-quality evidence), but not in another
1 that focused on children only.39 Intranasal fluticasone
furoate was associated with better rhinoconjunctivitis-
specific quality of life compared with placebo in people with
allergic rhinoconjunctivitis.41
Two systematic reviews with some overlap of primary
studies reported that adults with active uveitis who received
adalimumab, relative to those receiving placebo, had a greater
improvement in quality of life, but those with inactive uveitis
did not have improvements in quality of life with therapy.42,43
Surgery for people with trichiasis improved vision-related qual-
ity of life regardless of perioperative azithromycin adminis-
tration in 1 review.44 There were no differences in quality of
life among people with thyroid eye disease who received
radiotherapy or sham, according to 2 reviews45,46 based on
results from the same primary study.
Thirty-three interventions among specific populations
(eg, people with AMD, people with inactive disease, children
only) were identified, after accounting for duplicate interven-
tions assessed by multiple reviews and combining quality-of-
life outcomes (health-related, vision-related, or disease-
specific quality of life). A summary of findings table is presented
in Table 3. Overall, only 11 interventions23,24,33-35,39,42,43,45,46,54
were not associated with improved quality of life compared
with baseline or compared with a group receiving no inter-
vention: radiotherapy54 and supplementation with lutein and
zeaxanthin23,24 for AMD, supplementation with nutrients for
hereditary retinal dystrophies,33 early open-angle glaucoma
treatment with laser trabeculoplasty and topical β-blockers,34
open-angle glaucoma treatment with selective laser trabecu-
loplasty and/or medications,35 adalimumab for the treat-
ment of inactive uveitis (treatment improved quality of life
among those with active disease),42,43 radiotherapy for the
treatment of thyroid eye disease,45,46 and sublingual immu-
notherapy for rhinoconjunctivitis among children39 (how-
ever, this treatment improved quality of life in a review cov-
ering both children and adults40).
Comparisons of quality of life between 2 different oph-
thalmic interventions are presented in eTable 3 in the Supple-
ment. Similar quality of life was reported across the interven-
tions for most interventions compared. Interventions that were
associated with small or moderate improvements in quality of
life when compared with other interventions were immedi-
ate sequential cataract surgery compared with different date
bilateral cataract surgery (moderate-quality evidence),75 mul-
tifocal IOLs compared with monofocal IOLs (very low-quality
evidence in 1 review),55,60,61 toric IOLs compared with non-
toric IOLs,61 macular translocation compared with photody-
namic therapy (described as “insufficient evidence”70(p2)), the
use of handheld electronic devices with optical devices com-
pared with optical devices alone (moderate-quality evidence),71
vision rehabilitation using methods for enhancing vision
(eg, low-vision service, customized prism glasses) compared
with other interventions (moderate-quality evidence),36 and
posterior lamellar tarsal rotation surgery for minor trichiasis
compared with epilation.44
Discussion
In this umbrella review, we performed a global, broad assess-
ment of eye disease, vision impairment, and ophthalmic in-
terventions on quality of life. There was a consistent associa-
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tion between vision impairment and eye disease with reduced
quality of life across eye conditions, especially among adults.
Seventy-five percent of ophthalmic interventions evaluated
had evidence of a positive outcome on quality of life. Most
notably, cataract surgery and the use of anti-VEGF therapy for
AMD, diabetic macular edema, and macular edema second-
ary to other causes resulted in improved quality of life.
Vision impairment and eye diseases, namely glaucoma,
diabetic retinopathy, AMD, and retinitis pigmentosa were as-
sociated with lower quality of life, using a range of outcome
measures. Quantitative studies showed significant associa-
tions and sometimes a graded response, with worse vision im-
pairment being associated with worse quality of life. Qualita-
tive studies provided insight into the mechanisms of the
associations, specifically on well-being and functioning. While
the significant associations were expected, previous litera-
ture suggests that even more eye diseases are associated with
worse quality of life. Notably, dry eye has been studied exten-
sively, and a systematic review82 (excluded because of a lack
of appropriate criteria for critical appraisal) has suggested
that dry eye syndrome has a substantial association with re-
duced quality of life across countries in Europe, North America,
and Asia.
Ophthalmic interventions differed in their association with
quality of life. In general, treating cataract immediately after
diagnosis, even in those with competing eye conditions such
as AMD and who had already received a first cataract surgery,
improved quality of life. Moreover, anti-VEGF therapy for a
number of conditions, including AMD and diabetic macular
edema, and the use of corrective lenses for refractive error were
associated with improved quality of life. Projections from 2015
suggested that in 2020, 127.7 million people will have moder-
ate or severe vision impairment because of uncorrected re-
fractive error, 57.1 million because of cataract, 8.8 million be-
cause of AMD, and 3.2 million because of diabetic retinopathy.83
Three interventions (cataract surgery, corrective lenses, and
anti-VEGF therapy) provide opportunities to improve the qual-
ity of life of more than 150 million individuals globally. Other
interventions, such as treating rhinoconjunctivitis in chil-
dren and adults, trichiasis in endemic areas, and uveitis in those
with active and inactive disease, and low-vision rehabilita-
tion, also have the potential to improve quality of life.
The 8 interventions that were not found to improve qual-
ity of life included 2 that focused on specific populations. This
included the use of adalimumab, which did not improve qual-
ity of life among people with inactive uveitis but improved it
in those with active disease, and sublingual immunotherapy
for rhinoconjunctivitis, which did not improve quality of life
among children but improved it when people of all ages were
included in another review. Two of the interventions in-
volved nutritional supplements; one was lutein or zeaxan-
thin for AMD, and the other was nutritional supplements for
hereditary retinal dystrophies.
There were gaps in the evidence available on the out-
comes of leading causes of visual impairment (eg, cataract, re-
fractive error), among particular groups (eg, children, people
from racial/ethnic minorities), and in low- and middle-
income countries compared with high-income countries. In-
terventions for dry eye, refractive error, glaucoma, and dia-
betic retinopathy were underrepresented in this review in
comparison with their prevalence globally. While systematic
reviews about some topics may be lacking, there may be a lack
of primary studies as well: 70% of the interventional system-
atic reviews that aimed to assess quality of life outcomes were
subsequently excluded because they did not identify any pri-
mary studies reporting quality-of-life outcomes. Moreover,
almost half of the interventions and outcomes identified in
this review were comparing one intervention with another
without presenting information about the change in quality
of life from baseline in any of the groups, making it impos-
sible to know whether any of the interventions had an asso-
ciation with quality of life to begin with. While this may be
standard practice, as more and more eye diseases have well-
established treatments, delaying treatment or using placebo
control arms will not be possible. Thinking of ways to answer
questions about potential advantages of interventions with-
out depriving a group of beneficial therapy will be important.
Researchers could be encouraged to analyze and present data
such as overall changes from baseline values by treatment arm,
or regardless of treatment arm, even if they are not the pri-
mary outcomes.
The review process highlighted the need for a unified defi-
nition for quality of life to study and understand the associa-
tion with vision impairment and ophthalmic interventions on
well-being and vision function from the patient perspective.
Many systematic reviews were excluded because they con-
sidered patient satisfaction or patient-reported symptoms and
discomfort as quality-of-life measures. While these mea-
sures fall under the umbrella of patient-reported outcomes and
capture valuable information, they do not describe general
well-being or vision function in day-to-day life. Moreover, in
the included reviews, a wide range of quality of life measures
were used between and within the systematic reviews, which
limits the ability to compare findings between studies or com-
bine them into meta-analyses.
Limitations
Umbrella reviews findings are limited to results that have been
synthesized in published reviews, which may be affected by
publication bias themselves. Although this may have limited
the availability of studies about specific topics, it is this ap-
proach that allowed for a global assessment of a broad topic
in a systematic manner. Moreover, umbrella reviews are lim-
ited by the quality of the reviews and the data reported by
the reviews; not all reviews reported specific estimates, tools
used to measure outcomes, or enough context to interpret the
results. However, we applied strict criteria for systematic re-
views, including the working definition and critical appraisal
criteria used, and excluded reviews with case series. This ap-
proach may have further limited the number of systematic re-
views included, but it ensured the inclusion of reviews of higher
quality. Finally, there were overlaps in primary studies used
by the reviews, and many reviews reported findings based on
results from 1 or 2 primary studies only; these were presented
in both the text and Tables to allow readers to take them into
account when interpreting the findings.
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There is evidence that vision impairment and eye
diseases in general are associated with lower quality of
life, and most ophthalmic interventions are associated with
improved quality of life. Reviews and primary studies
addressing underrepresented diseases and reviews focusing
on specific populations, such as people from low- and
middle-income countries, are needed to expand generaliz-
able knowledge on the association between eye health and
quality of life.
Conclusions
Vision impairment and eye conditions are associated with lower
quality of life, and ophthalmic interventions can lead to sig-
nificant improvement in quality of life. Scaling up interven-
tions, such as cataract surgery, refractive error correction,
and anti-VEGF therapy at a global level, has the potential to
improve the quality of life of millions of people worldwide.
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